FDA halts study of Sarepta treatment for Duchenne muscular dystrophy due to safety concern - STAT
arepta Therapeutics said Thursday that it has temporarily stopped a clinical trial of its second-generation medicine for patients with a certain type of Duchenne muscular dystrophy due to a serio...
Read more